

# **Supplementary Figures**


Early prolonged prone position in noninvasively ventilated patients with SARS-CoV-2related moderate-to-severe hypoxemic respiratory failure: clinical outcomes and mechanisms for treatment response in the PRO-NIV study




**Supplementary Figure 2.** Propensity score(PS) density in PP and controls before and after matching (panel A) and balance plots of logit(PS) in PP and controls before and after matching(panel B)

Panel A: Propensity Score Distribution before and after matching






Panel B: balance plots of logit (Propensity Score) in PP and controls before and after matching




**Supplementary Figure 3.** Total daily hours of NIV and of NIV in prone position in both groups during the initial 7 study days in the whole study populaton (n=243). Bars represent the median, whiskers the IQR1 and IQR3




**Supplementary Figure 4.** NIV failure, death and endotracheal intubation in patients grouped according to paO2/FiO2 at admission: paO2/FiO2<100 vs paO2/FiO2 100-199


Panel A: NIV failure in patients with paO2/FiO2<100




Panel B: NIV failure in patients with paO2/FiO2≥100




Panel C: death in patients with paO2/FiO2<100




Panel D: death in patients with paO2/FiO2≥100



Panel E: endotracheal intubation in patients with paO2/FiO2<100




Panel F: endotracheal intubation in patients with paO2/FiO2≥100




**Supplementary Figure 5.** NIV failure, death and endotracheal intubation in the prone position group vs. controls enrolled the 1<sup>st</sup> pandemic wave (March 1<sup>st</sup>-June 30<sup>th</sup>, 2020) or the 2<sup>nd</sup> pandemic wave (July 1<sup>st</sup>-Dec 15<sup>th</sup>, 2020).


### Panel A: NIV failure (controls from the 1st wave)



Panel B: NIV failure (controls from the 2nd wave)



**Panel C: death (controls from the 1st wave)** 



controls 1st waveprone position

Number at risk

Group: controls 1st wave

5

10

79 65 57 54 50 50 0

15 days 20

25


30

Group: prone position

81 81 79 74 73 71 0

Panel D: death (controls from the 2nd wave)

cumulative incidence of death at 28 days



controls 2nd waveprone position

Number at risk


Group: controls 2nd wave

83 79 62 55 53 53 0


Group: prone position

81 81 79 74 73 71 0


Panel E: endotracheal intubation (controls from the 1st wave)



Panel F: endotracheal intubation (controls from the 2nd wave)




**Supplementary Figure 6**: correlation between global lung ultrasound (LUS) score and global chest computed tomography (CT) severity score, as proposed by Salaffi et al. in 162 patients with SARS-CoV-2-related acute hypoxemic respiratory failure admitted to the Subintensive Care Unit. The median (IQR) CT severity score was 46(32, 60) and the median (IQR) LUS severity score was 25(21, 30). The Spearman correlation coefficient ( $r_s$ ) with its 95%CI and statistical significance are shown in the Figure.




**Supplementary Figure 7.** Relationship between dead space index corrected Minute Ventilation (MVcorr)] and NIV failure, death and ETI within each paO2/FiO2 quartile at timepoint sp1(i.e. supine position at day 1, corresponding in the PP group to resupination after the first 8-hr overnight PP session)(n=182). paO2/FiO2 range within each quartile and PEEP (median, IQR) at which measurements were made are reported at the bottom of the panels.

\* P<0.05 vs. treatment failure within quartile # P<0.001 vs. controls


Panel A: MVcorr and NIV failure



Panel B: MVcorr and death




Panel C; MVcorr and ETI




**Supplementary Figure 8.** Impact of O2-response and CO2-response on NIV failure, death and ETI. CO2-response was assessed via corrected Minute Ventilation(MVcorr).

# P<0.01 vs. other groups  $\P$  P<0.001 vs. other groups


## Panel A



### Panel B



# Panel C



**Supplementary Figure 9**: serum procalcitonin in PP group and controls after excluding patients with documented (either at admission or after admission to Subintensive Care Unit) bacterial or mycotic infection (n=223)

